Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest & Investment Income: 2022-2025

Historic Interest & Investment Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $1.4 million.

  • Phathom Pharmaceuticals' Interest & Investment Income fell 61.92% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year decrease of 37.65%. This contributed to the annual value of $15.2 million for FY2024, which is 92.46% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Interest & Investment Income stood at $1.4 million for Q3 2025, which was down 20.93% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Interest & Investment Income ranged from a high of $4.3 million in Q1 2024 and a low of $7,000 during Q1 2022.
  • In the last 3 years, Phathom Pharmaceuticals' Interest & Investment Income had a median value of $2.7 million in 2023 and averaged $2.6 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first soared by 20,757.14% in 2023, then crashed by 61.92% in 2025.
  • Phathom Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $1.3 million in 2022, then surged by 160.14% to $3.3 million in 2023, then increased by 4.84% to $3.5 million in 2024, then tumbled by 61.92% to $1.4 million in 2025.
  • Its Interest & Investment Income stands at $1.4 million for Q3 2025, versus $1.8 million for Q2 2025 and $2.6 million for Q1 2025.